Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 21;37:107. doi: 10.1186/s13046-018-0772-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 5 — The effect of co-treatment of olaparib and doxorubicin on the proliferation of osteosarcoma cells. a Co-treatment of the PARP inhibitor, olaparib, and doxorubicin significantly inhibited the growth of U2OS, SaOS2, MG63, and KHOS/NP cells compared with individual treatment of olaparib or doxorubicin in MTT and colony forming assay. b Soft agar assay showed significantly decreased proliferation of U2OS, SaOS2, and MG63 cells with co-treatment of 10 μM of olaparib and 0.2 μM of doxorubicin (magnification, × 100). *, versus control, P < 0.05; **, versus control, P < 0.001; †, versus doxorubicin, P < 0.05; ††, versus doxorubicin, P < 0.001